Patrick D. Walsh net worth and biography

Patrick Walsh Biography and Net Worth

Director of ANI Pharmaceuticals

Mr. Walsh has served as a director since May 2018 and has been Chairman of the Board since June 2020. He also served as interim Chief Executive Officer of ANI from May 2020 to September 2020. In March 2021, Mr. Walsh was appointed as Chairman and Chief Executive Officer of Alcami, a global pharmaceutical contract development and manufacturing organization. Mr. Walsh co-founded TriPharm Services, an injectable manufacturing business which was acquired by Alcami, and served as its Chief Executive Officer from May 2019 to April 2020. From 2015 to February 2019, Mr. Walsh was the Chief Executive Officer of Avista Pharma, a private equity-backed global provider of contract manufacturing, development and analytical testing services that was acquired by Cambrex. Mr. Walsh’s earlier career includes serving as Chief Executive Officer of AAIPharma Services Corporation in Wilmington, North Carolina, a global provider of contract manufacturing services that was acquired in 2014, as Chief Executive Officer of Kadmus Pharma, which was acquired by Organon Pharma, and also serving as President and Chief Operating Officer and board member of publicly-traded Gensia-Sicor, which was acquired by Teva.

Mr. Walsh currently serves as an independent board of director of Avid Bioservices (NASDAQ: CDMO), an independent director of Landec Corp (NASDAQ: LNDC), and an independent director of Industria Chemica Emiliano (I.C.E), a private-equity backed specialty chemical company based in Milan, Italy. Mr. Walsh is an Operating Partner (part-time) at healthcare private equity firm Ampersand Capital and is also Chairman and founder of Diligence Group LLC based in Durham, North Carolina.

What is Patrick D. Walsh's net worth?: The estimated net worth of Patrick D. Walsh is at least $2.70 million as of April 20th, 2021. Mr. Walsh owns 40,000 shares of ANI Pharmaceuticals stock worth more than $2,704,400 as of March 30th. This net worth estimate does not reflect any other assets that Mr. Walsh may own. Learn More about Patrick D. Walsh's net worth.
How do I contact Patrick D. Walsh?: The corporate mailing address for Mr. Walsh and other ANI Pharmaceuticals executives is 210 Main Street West, Baudette MN, 56623. ANI Pharmaceuticals can also be reached via phone at (218) 634-3500 and via email at ir@anipharmaceuticals.com. Learn More on Patrick D. Walsh's contact information.
Has Patrick D. Walsh been buying or selling shares of ANI Pharmaceuticals?: Patrick D. Walsh has not been actively trading shares of ANI Pharmaceuticals during the past quarter. Most recently, on Monday, March 21st, Patrick D. Walsh bought 5,000 shares of ANI Pharmaceuticals stock. The stock was acquired at an average cost of $27.76 per share, with a total value of $138,800.00. Learn More on Patrick D. Walsh's trading history.
Who are ANI Pharmaceuticals' active insiders?: ANI Pharmaceuticals' insider roster includes Stephen Carey (CFO), Stephen Carey (Senior Vice President, Finance and Chief Financial Officer), Meredith Cook (Senior Vice President, General Counsel and Corporate Secretary), Krista Davis (Senior Vice President and Chief Human Resources Officer), Chad Gassert (Senior Vice President, Corporate Development and Strategy), Ori Gutwerg (Senior Vice President, Generics), Thomas Haughey (Director), Nikhil Lalwani (Pres), Nikhil Lalwani (President and Chief Executive Officer), James Marken (Senior Vice President, Operations and Product Development), Christopher Mutz (Insider), Antonio Pera (Director), Muthusamy Shanmugam (Head of R&D and COO of NJ Operations), Muthusamy Shanmugam (Head of R&D and COO), Renee Tannenbaum (Director), Jeanne Thoma (Director), and Patrick Walsh (Director). Learn More on ANI Pharmaceuticals' active insiders.
Are insiders buying or selling shares of ANI Pharmaceuticals?: During the last year, insiders at the specialty pharmaceutical company sold shares 33 times. They sold a total of 268,126 shares worth more than $16,946,714.15. The most recent insider tranaction occured on March, 13th when VP Meredith Cook sold 400 shares worth more than $25,332.00. Insiders at ANI Pharmaceuticals own 12.7% of the company. Learn More about insider trades at ANI Pharmaceuticals.
Information on this page was last updated on 3/13/2025.

Patrick D. Walsh Insider Trading History at ANI Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/21/2022	Buy	5,000	$27.76	$138,800.00
3/15/2021	Buy	4,000	$32.89	$131,560.00	39,096
11/9/2020	Buy	5,000	$25.96	$129,800.00	35,096
8/10/2020	Buy	10,000	$30.78	$307,800.00	23,096

Patrick D. Walsh Buying and Selling Activity at ANI Pharmaceuticals

ANI Pharmaceuticals Company Overview

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. It markets its products through retail pharmacy chains, wholesalers, distributors and mail order pharmacies, group purchasing organizations, specialty pharmacies, and hospitals. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Today's Range

Now: $67.61

$67.02

$68.49

50 Day Range

MA: $60.49

$54.51

$68.36

2 Week Range

Now: $67.61

$52.50

$70.00

Volume

355,964 shs

Average Volume

256,304 shs

Market Capitalization

$1.47 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.63